CytoMed Therapeutics

What CytoMed Therapeutics does

CytoMed Therapeutics is a Singapore-based clinical-stage biotechnology company that develops allogeneic Gamma Delta T cell cancer therapies targeting both solid tumors and hematological malignancies. The company originated as a spin-off from ASTAR (Singapore's Agency for Science, Technology and Research) and is publicly listed on NASDAQ under ticker GDTC, with a headcount of 11-50 employees. Its core platform centers on off-the-shelf allogeneic gamma delta T cell treatments designed to be affordable and accessible, and in November 2025 the company expanded its technology base by completing the acquisition of TC BioPharm Limited's TCB-002 allogeneic gamma delta T cell technology, which it plans to adapt for China and India markets leveraging favorable regulatory frameworks such as China's Directive 818.

The company monetizes through eventual commercialization of cell-based immunotherapies, though it remains pre-revenue at present. CytoMed is pursuing hospital partnerships and medical tourism channels in Southeast Asia as its go-to-market approach, with a strategic expansion posture toward China and India. Its clinical pipeline is anchored by the Singapore ANGELICA trial, which has completed treatment for 6 of 12 planned patients, with a Malaysian trial planned for 2026. Through the acquisition of Longevity Bank in Malaysia, CytoMed added cord blood resources and an autologous cell therapy subsidiary (LongevityBank), which secured USD 500,000 in non-dilutive funding from ICH Capital. The company's customer base, as currently defined, consists of oncology patients treated via hospital partners and clinical trial sites, with no commercial revenue or disclosed customer pricing.

CytoMed's growth posture is shaped by the broader biotech funding downturn. The chairman has explicitly framed recent acquisitions and geographic expansion as a 'survival strategy,' and the company raised only USD 8 million at IPO under heavy short-selling pressure. Nonetheless, the TC BioPharm and LongevityBank acquisitions, combined with regulatory positioning in China and India, represent substantive moves to broaden the platform's therapeutic reach and geographic optionality.

Name

CytoMed Therapeutics

Legal name

CytoMed Therapeutics Ltd

Website

https://cytomed.sg

Company type

Public

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

CytoMed Therapeutics is a Singapore-based clinical-stage biotech (NASDAQ: GDTC) developing allogeneic Gamma Delta T cell immunotherapies for solid tumors and hematological malignancies, targeting hospital and medical tourism channels across Southeast Asia, China, and India.

Ownership category

akta.pro rank

Product category

Cancer Immunotherapy

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell Therapy Developers (Autologous) (HLAAABAA)

akta.pro secondary industry

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• Allogeneic cell therapy
• Gamma delta T cell
• Cancer immunotherapy
• Cell-based therapeutics
• Solid tumor treatment

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Cancer Immunotherapy Development: Clinical-stage biotech developing cell-based immunotherapies for cancer treatment. Revenue model based on eventual commercialization of therapies through hospital partnerships and medical tourism in Southeast Asia, with strategic positioning in China and India markets.

Go-to-market motion1 record

Distribution channels1 record

Core offering

CytoMed Therapeutics is a clinical-stage biotech developing off-the-shelf allogeneic gamma delta T cell cancer therapies that target both solid tumors and hematological malignancies. Its core platform is being advanced through the ANGELICA trial in Singapore and a planned Malaysian trial for 2026, with strategic positioning in China and India via favorable regulatory frameworks such as China's Directive 818.

Product overview

CytoMed Therapeutics is a clinical-stage biotech company developing a unified portfolio of allogeneic Gamma Delta T Cell cancer therapies. The core product is an off-the-shelf cell therapy platform for treating solid tumors and hematological malignancies. The company expanded its capabilities through the acquisition of TCB-002 technology from TC BioPharm and operates LongevityBank as a subsidiary focused on autologous cell therapies using cord blood resources.

Differentiator

Problem solved

Functional benefit

Brands

• LongevityBank: Subsidiary focusing on autologous cell therapies, acquired by CytoMed Therapeutics

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core.

• TC BioPharm LimitedcoreTechnology or Integration · 18 November 2025CytoMed completed acquisition of TC BioPharm's allogeneic gamma delta T cell technology (TCB-002) to develop cell-based immunotherapies for cancer. The acquisition enhances CytoMed's expertise in allogeneic cell therapies and accelerates commercial timeline.
• Longevity Bank (Malaysia)coreStrategic or Co-development PartnerAcquired Longevity Bank for cord blood resources, providing access to cell therapy resources and expertise in autologous cell therapies.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Adicet Bio: Adicet Bio is a clinical-stage biotech developing allogeneic gamma delta T cell therapies for cancer, making it the closest direct peer to CytoMed's core TCB-002 platform and shared indication focus.
• Allogene Therapeutics: Allogene is a leading allogeneic CAR-T developer with multiple clinical programs in hematologic malignancies, directly comparable to CytoMed's allogeneic, off-the-shelf cell therapy model and oncology focus.
• Adaptimmune Therapeutics: Adaptimmune develops engineered T cell receptor (TCR) therapies for solid tumors, sharing CytoMed's T cell engineering approach and solid tumor focus, though with an autologous/spearhead product profile.
• Cellectis: Cellectis develops allogeneic CAR-T therapies using gene-editing platforms, sharing CytoMed's allogeneic cell therapy modality and oncology indications, with similar early-stage clinical positioning.
• Immatics: Immatics develops TCR-based immunotherapies for solid tumors, comparable to CytoMed's T cell receptor-mediated approach and overlapping solid tumor indications.
• Marker Therapeutics: Marker Therapeutics develops non-engineered, multi-tumor-associated antigen-specific T cell therapies for cancer, comparable in modality (T cell therapy) and clinical-stage scale to CytoMed.

Emerging players

• CRISPR Therapeutics: CRISPR Therapeutics applies gene editing to cell therapies (including allogeneic CAR-T), overlapping with CytoMed's cell engineering approach but with a broader gene-editing-enabled pipeline.

Broad incumbents

• Bristol Myers Squibb: Bristol Myers Squibb markets approved CAR-T therapies (Breyanzi, Abecma) through its Celgene franchise, representing a large incumbent with overlapping cell therapy and oncology indications.
• Gilead Sciences (Kite): Gilead's Kite Pharma subsidiary markets Yescarta and Tecartus, approved autologous CAR-T therapies for hematologic malignancies — directly overlapping CytoMed's target indications at commercial scale.
• Takeda Pharmaceutical: Takeda is a global oncology and cell therapy participant (e.g., through partnerships on allogeneic platforms), relevant as a broad incumbent with Asia-Pacific commercial reach comparable to CytoMed's target geography.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CytoMed Therapeutics